Knight Therapeutics Inc.

Good morning, ladies and gentlemen. My name is Paul, and I will be your operator today. Welcome to Knight Therapeutics Inc. 2021 First Quarter Financial Results Conference Call. Before turning the call over to Jonathan Ross Goodman, CEO of Knight, listeners are reminded that portions of today's discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law. We would also like to remind you questions during today's call will be taken from analysts only. Should there be any further questions, please contact Knight's Investor Relations Department via email to info at knighttx.com or via phone at 514-678-8930. I would like to remind everyone that this call is being recorded today, May 14th, 2021, and would now like to turn the meeting over to your host for today's call, Jonathan Ross Goodman. Please go ahead, Mr. Goodman.

Good morning, everyone, and welcome to Knight Therapeutics' first quarter 2021 conference call. I am joined on today's call with Samira Sakia, our President and Chief Operating Officer, Amal Khoury, our Chief Business Development Officer, Arvind Uchana, our Chief Financial Officer, and Jeff Martins, our VP Commercial. Since Sunday night in 2014, we have set out to build a rest-of-the-world pharmaceutical company that brings innovative products that help the lives of patients. Since our 2014 founding, NetApp deployed or invested over $900 million of capital, while generating over $270 million in net income. Today, we commercialize pharmaceuticals in Canada and 10 Latin American countries with nearly 700 talented people. We are in the business of making people better while creating shareholder value. I have been faithfully reporting quarterly results to shareholders for the last 27 years or 104 quarters. Effective September 1st, 2021, I will assume the role of executive chairman and then talented and get stuff done, Samar Sakhia will assume the role of president and CEO. In addition, Jim Gale, who has been Knight's chairman since founding, will transition to the role of lead director. I will continue to direct Knight's strategy and remain focused on non-operational areas where I can add the most value. I have worked side by side with Samira for 18 years, where I've had the privilege of watching her develop into a seasoned top brass executive. Knight is my baby, and I would only entrust its tutorship to the best and brightest. I will now turn over the call to Samira, who will walk through our corporate updates.

Thank you Jonathan and good morning everyone, as I said yesterday, I started a CFO pattern in the summer of 2001 and it has been a privilege to have worked hand in hand with and learn from Jonathan for the last 20 years. i'm honored and humbled to take on the role of presidency of night and to lead an exceptionally talented dedicated dedicated executive team and nights across Canada and Latin America. Over the last 18 months, we have executed on a transformational acquisition and remain focused on executing on our strategy of building on our Pan-American ex-U.S. footprint. We will continue on our mission to license late-stage innovative products, acquire under-promoted products from Big Pharma, and develop branded generic products that improve the lives of patients in Canada and Latin America. As for the quarter, I'm excited to report that our key launch brands in Latin America, including Chris Semba, Halibut, and Linvima, as well as Trailstar and Merlinx in Canada, grew 116% combined compared to the same period last year. Subsequent to the quarter, we executed on another transformation transaction with the acquisition of Exelon from Novartis for Canada and Latin America. Turning now to the NCIB, which we launched in July last year. Under this NCIB, Knight can purchase up to 10.9 million common shares until July 2021. During the quarter, we purchased approximately 3.6 million common shares for an aggregate cash consideration of 18.6 million dollars. Subsequent to the quarter, we've purchased an additional 512,000 common shares for an aggregate cash consideration of 2.7 million dollars. I'll now turn the call over to Amal for an update on BD activities.